Shots:
- Alvotech has entered into supply & commercialization agreements with Sandoz for multiple biosimilar candidates across Canada, Australia, & New Zealand
- In Canada, the deal includes one ophthalmology biosimilar in a prefilled intravitreal syringe, while in Australia & New Zealand, it covers 3 biosimilar candidates across immunology & gastroenterology in multiple formulations
- As per the deals, Alvotech will handle development, global clinical activities, manufacturing & finished product supply, while Sandoz will be responsible for regulatory filings, commercialization & distribution
Ref: Globenewswire |  Image: Alvotech & Sandoz  | Press Release
Related News: Alvotech and Advanz Pharma Report the EMA’s MAA Acceptance of AVT23 (Biosimilar, Xolair)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
